Format

Send to

Choose Destination
Drug Des Devel Ther. 2017 Aug 2;11:2265-2276. doi: 10.2147/DDDT.S135571. eCollection 2017.

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.

Author information

1
Department of Biochemistry and Genetics, School of Medicine.
2
Department of Pharmaceutical Analysis, College of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China.

Abstract

Antibody-drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis. Conjugation strategies, endocytosis and intracellular trafficking optimization, linkers, and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully. This inventiveness of endocytosis and intracellular trafficking has given considerable momentum recently to develop specific antibodies and ADCs to treat cancer cells. It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment. Current studies illustrate endocytosis and intracellular trafficking of ADC, protein, and linker strategies in unloading and also concisely evaluate practically applicable ADCs.

KEYWORDS:

antibody; antibody–drug conjugate; clathrin; endocytosis; intracellular trafficking

PMID:
28814834
PMCID:
PMC5546728
DOI:
10.2147/DDDT.S135571
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center